Beacon Financial Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
VCM
VPM
Beacon Financial Advisory's VRTX Position: Q1 2026 in Review
Beacon Financial Advisory increased its Vertex Pharmaceuticals (VRTX) stake by 5% in Q1 2026, buying an estimated $12.6K and bringing the position to 569 shares worth $254K. The position accounts for 0.06% of the portfolio, ranked #345.
Beacon Financial Advisory first reported a position in VRTX in Q4 2023 and has held it in 6 quarters since. The position peaked at $258K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Beacon Financial Advisory held 569 shares of Vertex Pharmaceuticals worth $254K as of Q1 2026.
- Beacon Financial Advisory bought 27 Vertex Pharmaceuticals shares in Q1 2026, an estimated $12.6K.
- Vertex Pharmaceuticals made up 0.06% of Beacon Financial Advisory's portfolio in Q1 2026, its #345 holding.
- Beacon Financial Advisory first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 6 quarters since.
- Beacon Financial Advisory's Vertex Pharmaceuticals position peaked at $258K in Q1 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Beacon Financial Advisory's 13F filing for Q1 2026, filed 27 Apr 2026.